Give Wing a reassuring treatment experience

WingKaraokeImage.png

Quality of life is getting ever more 

important in the treatment of ALK+ 

NSCLC. With ALECENSA, patients 

experience HRQoL improvements 

within 8 weeks of starting therapy 

and this improvement lasts 5 months 

longer than the improvement seen 

with crizotinib.

  • 37 year-old
  • Primary school teacher
  • Loves to sing
  • Lifelong non-smoker

Efficacy that translates into sustained
quality of life improvement1,4

treatment-graph.jpg

Efficacy that translates into sustained quality of life improvement1,4

ALEX phase III: clinically
meaningful improvement
in HRQoL* (≥10 point
increase)4†

chart-treatment-experience-1@2x.png

*Changes in HRQoL and functioning were assessed using the European Organisation for Research and Treatment of Cancer (EORTC). †1 month equal to 4.3 weeks.

Quality of Life Questionnaire (QLQ)-C30 and the QLQ lung cancer module (LC13)2. HRQoL: health-related quality of life.

*Changes in HRQoL and functioning were assessed using the European Organisation for Research and Treatment of Cancer (EORTC). †1 month equal to 4.3 weeks.

Quality of Life Questionnaire (QLQ)-C30 and the QLQ lung cancer module (LC13)2. HRQoL: health-related quality of life.

WingonCouchImage.png

Tolerability is key to helping patients 

take their medication. With over 52,000 

patients treated to date,11 ALECENSA 

has consistently demonstrated a 

well-known and manageable 

safety profile

 

Favourable safety and tolerability profile with nearly 3x longer median treatment duration*1

ALEX phase III: overview
of adverse events1

  ALECENSA
(n=152)
Crizotinib
(n=151)
Event Any Grade (%) Grade 3-5 (%) Any Grade (%) Grade 3-5 (%)
Adverse Event 97 52 97 56
Serious adverse event 39 32
Adverse event leading to treatment discontinuation 15 15
Adverse event leading to dose reduction 20 20
Adverse event leading to dose interruption 26 27

*The median duration of treatment with ALECENSA was 28.1 months vs 10.8 months with crizotinib1

5 years
no new safety
signals1

Low treatment discontinuation or dose reduction rates1

Due to adverse events (relative to crizotinib).1

1. Mok T et al. Ann Oncol. 2020;31(8):1056–64. 4. Pérol M et al. Lung Cancer. 2019;138:79–87. 11. Roche data on file ( PBRER PSUR), 2020.

Due to adverse events (relative to crizotinib).1

1. Mok T et al. Ann Oncol. 2020;31(8):1056–64. 4. Pérol M et al. Lung Cancer. 2019;138:79–87. 11. Roche data on file ( PBRER PSUR), 2021.

Continue to

How ALECENSA works